UNRESECTABLE PANCREATIC CARCINOMA
Clinical trials for UNRESECTABLE PANCREATIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE PANCREATIC CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE PANCREATIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in people with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 adults with cance…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Could a diabetes drug and supplements boost chemo for pancreatic cancer?
Disease control OngoingThis early-phase study tests whether adding the diabetes drug metformin and a specific dietary supplement mix to standard chemotherapy is safe and feasible for people with pancreatic cancer that cannot be removed by surgery. The supplement includes ingredients like curcumin, vita…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug combo targets tough cancers: hope for liver, pancreas, and bile duct tumors
Disease control OngoingThis early-phase study tests a combination of two drugs, guadecitabine and durvalumab, in people with advanced liver, pancreatic, bile duct, or gallbladder cancer that has spread. The main goals are to find the safest dose and see if the drugs can shrink tumors. About 55 particip…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC